155 related articles for article (PubMed ID: 19642143)
1. EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma.
Cui XD; Lee MJ; Yu GR; Kim IH; Yu HC; Song EY; Kim DG
Int J Cancer; 2010 Feb; 126(4):940-9. PubMed ID: 19642143
[TBL] [Abstract][Full Text] [Related]
2. Association between ephrin-A1 mRNA expression and poor prognosis after hepatectomy to treat hepatocellular carcinoma.
Wada H; Yamamoto H; Kim C; Uemura M; Akita H; Tomimaru Y; Hama N; Kawamoto K; Kobayashi S; Eguchi H; Umeshita K; Doki Y; Mori M; Nagano H
Int J Oncol; 2014 Sep; 45(3):1051-8. PubMed ID: 24969670
[TBL] [Abstract][Full Text] [Related]
3. [Expression and clinical significance of Ephrin-A1 in primary hepatocellular carcinoma].
Zhang G; Zhang SJ; Zhao YF; Wu Y; Li Z; Wang JX
Zhonghua Wai Ke Za Zhi; 2007 Apr; 45(7):499-502. PubMed ID: 17686315
[TBL] [Abstract][Full Text] [Related]
4. Ephrin-A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing hepatocellular carcinoma.
Iida H; Honda M; Kawai HF; Yamashita T; Shirota Y; Wang BC; Miao H; Kaneko S
Gut; 2005 Jun; 54(6):843-51. PubMed ID: 15888795
[TBL] [Abstract][Full Text] [Related]
5. Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder.
Abraham S; Knapp DW; Cheng L; Snyder PW; Mittal SK; Bangari DS; Kinch M; Wu L; Dhariwal J; Mohammed SI
Clin Cancer Res; 2006 Jan; 12(2):353-60. PubMed ID: 16428472
[TBL] [Abstract][Full Text] [Related]
6. EPHA2/EFNA1 expression in human gastric cancer.
Nakamura R; Kataoka H; Sato N; Kanamori M; Ihara M; Igarashi H; Ravshanov S; Wang YJ; Li ZY; Shimamura T; Kobayashi T; Konno H; Shinmura K; Tanaka M; Sugimura H
Cancer Sci; 2005 Jan; 96(1):42-7. PubMed ID: 15649254
[TBL] [Abstract][Full Text] [Related]
7. Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma.
Ma H; Liang X; Chen Y; Pan K; Sun J; Wang H; Wang Q; Li Y; Zhao J; Li J; Chen M; Xia J
Int J Cancer; 2011 Feb; 128(4):771-7. PubMed ID: 20473897
[TBL] [Abstract][Full Text] [Related]
8. Higher expression of EphA2 and ephrin-A1 is related to favorable clinicopathological features in pathological stage I non-small cell lung carcinoma.
Ishikawa M; Miyahara R; Sonobe M; Horiuchi M; Mennju T; Nakayama E; Kobayashi M; Kikuchi R; Kitamura J; Imamura N; Huang CL; Date H
Lung Cancer; 2012 Jun; 76(3):431-8. PubMed ID: 22236865
[TBL] [Abstract][Full Text] [Related]
9. Inducible nitric oxide synthase and survivin messenger RNA expression in hepatocellular carcinoma.
Ikeguchi M; Ueta T; Yamane Y; Hirooka Y; Kaibara N
Clin Cancer Res; 2002 Oct; 8(10):3131-6. PubMed ID: 12374680
[TBL] [Abstract][Full Text] [Related]
10. Lack of ephrin receptor A1 is a favorable independent prognostic factor in clear cell renal cell carcinoma.
Toma MI; Erdmann K; Diezel M; Meinhardt M; Zastrow S; Fuessel S; Wirth MP; Baretton GB
PLoS One; 2014; 9(7):e102262. PubMed ID: 25025847
[TBL] [Abstract][Full Text] [Related]
11. Decreased expression of SOX6 confers a poor prognosis in hepatocellular carcinoma.
Guo X; Yang M; Gu H; Zhao J; Zou L
Cancer Epidemiol; 2013 Oct; 37(5):732-6. PubMed ID: 23731550
[TBL] [Abstract][Full Text] [Related]
12. EphA2/ephrinA1 mRNA expression and protein production in adenoid cystic carcinoma of salivary gland.
Shao Z; Zhu F; Song K; Zhang H; Liu K; Shang Z
J Oral Maxillofac Surg; 2013 May; 71(5):869-78. PubMed ID: 23298804
[TBL] [Abstract][Full Text] [Related]
13. Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.
Sukka-Ganesh B; Mohammed KA; Kaye F; Goldberg EP; Nasreen N
BMC Cancer; 2012 Jul; 12():309. PubMed ID: 22824143
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma.
Zhou ZJ; Dai Z; Zhou SL; Fu XT; Zhao YM; Shi YH; Zhou J; Fan J
Int J Cancer; 2013 Mar; 132(5):1080-9. PubMed ID: 22821376
[TBL] [Abstract][Full Text] [Related]
15. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations.
Peng SY; Chen WJ; Lai PL; Jeng YM; Sheu JC; Hsu HC
Int J Cancer; 2004 Oct; 112(1):44-50. PubMed ID: 15305374
[TBL] [Abstract][Full Text] [Related]
16. Methylation of IRAK3 is a novel prognostic marker in hepatocellular carcinoma.
Kuo CC; Shih YL; Su HY; Yan MD; Hsieh CB; Liu CY; Huang WT; Yu MH; Lin YW
World J Gastroenterol; 2015 Apr; 21(13):3960-9. PubMed ID: 25852282
[TBL] [Abstract][Full Text] [Related]
17. Identification of cystatin B as a potential serum marker in hepatocellular carcinoma.
Lee MJ; Yu GR; Park SH; Cho BH; Ahn JS; Park HJ; Song EY; Kim DG
Clin Cancer Res; 2008 Feb; 14(4):1080-9. PubMed ID: 18281540
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma.
Lee NP; Tsang FH; Shek FH; Mao M; Dai H; Zhang C; Dong S; Guan XY; Poon RT; Luk JM
Int J Cancer; 2010 Aug; 127(4):968-76. PubMed ID: 19998337
[TBL] [Abstract][Full Text] [Related]
19. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
[TBL] [Abstract][Full Text] [Related]
20. Expression of hepatoma-derived growth factor in hepatocellular carcinoma.
Hu TH; Huang CC; Liu LF; Lin PR; Liu SY; Chang HW; Changchien CS; Lee CM; Chuang JH; Tai MH
Cancer; 2003 Oct; 98(7):1444-56. PubMed ID: 14508832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
